304 related articles for article (PubMed ID: 29239900)
1. Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis.
Freiman JM; Jacobson KR; Muyindike WR; Horsburgh CR; Ellner JJ; Hahn JA; Linas BP
J Acquir Immune Defic Syndr; 2018 Apr; 77(4):405-412. PubMed ID: 29239900
[TBL] [Abstract][Full Text] [Related]
2. Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting.
Kendall EA; Azman AS; Maartens G; Boulle A; Wilkinson RJ; Dowdy DW; Rangaka MX
AIDS; 2019 Mar; 33(3):525-536. PubMed ID: 30325773
[TBL] [Abstract][Full Text] [Related]
3. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
[TBL] [Abstract][Full Text] [Related]
4. Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy.
Sumner T; Houben RM; Rangaka MX; Maartens G; Boulle A; Wilkinson RJ; White RG
AIDS; 2016 May; 30(8):1279-86. PubMed ID: 26950316
[TBL] [Abstract][Full Text] [Related]
5. Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic.
Kunkel A; Crawford FW; Shepherd J; Cohen T
AIDS; 2016 Nov; 30(17):2715-2723. PubMed ID: 27782966
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data.
Karanja M; Kingwara L; Owiti P; Kirui E; Ngari F; Kiplimo R; Maina M; Masini E; Onyango E; Ngugi C
PLoS One; 2020; 15(12):e0234588. PubMed ID: 33264300
[TBL] [Abstract][Full Text] [Related]
7. Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe.
Nyathi S; Dlodlo RA; Satyanarayana S; Takarinda KC; Tweya H; Hove S; Matambo R; Mandewo W; Nyathi K; Sibanda E; Harries AD
PLoS One; 2019; 14(10):e0223076. PubMed ID: 31581271
[TBL] [Abstract][Full Text] [Related]
8. Strategies for isoniazid preventive therapy in HIV-positive patients who consume alcohol.
Savinkina A; Muyindike W; Hahn JA; Emenyonu NI; Fatch R; Ngabirano C; Adong J; Jacobson KR; Linas BP
Int J Tuberc Lung Dis; 2024 Jul; 28(7):335-342. PubMed ID: 38961548
[TBL] [Abstract][Full Text] [Related]
9. A Description of Mortality Associated with IPT plus ART Compared to ART Alone among HIV-Infected Individuals in Addis Ababa, Ethiopia: A Cohort Study.
Edessa D; Likisa J
PLoS One; 2015; 10(9):e0137492. PubMed ID: 26348618
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study.
Semu M; Fenta TG; Medhin G; Assefa D
BMC Infect Dis; 2017 Jan; 17(1):5. PubMed ID: 28049455
[TBL] [Abstract][Full Text] [Related]
11. Implementation and Operational Research: Implementation of the WHO 2011 Recommendations for Isoniazid Preventive Therapy (IPT) in Children Living With HIV/AIDS: A Ugandan Experience.
Costenaro P; Massavon W; Lundin R; Nabachwa SM; Fregonese F; Morelli E; Alowo A; Nannyonga Musoke M; Namisi CP; Kizito S; Bilardi D; Mazza A; Cotton MF; Giaquinto C; Penazzato M
J Acquir Immune Defic Syndr; 2016 Jan; 71(1):e1-8. PubMed ID: 26761275
[TBL] [Abstract][Full Text] [Related]
12. Challenges and opportunities to prevent tuberculosis in people living with HIV in low-income countries.
Harries AD; Schwoebel V; Monedero-Recuero I; Aung TK; Chadha S; Chiang CY; Conradie F; Dongo JP; Heldal E; Jensen P; Nyengele JPK; Koura KG; Kumar AMV; Lin Y; Mlilo N; Nakanwagi-Mukwaya A; Ncube RT; Nyinoburyo R; Oo NL; Patel LN; Piubello A; Rusen ID; Sanda T; Satyanarayana S; Syed I; Thu AS; Tonsing J; Trébucq A; Zamora V; Zishiri C; Hinderaker SG; Aït-Khaled N; Roggi A; Caminero Luna J; Graham SM; Dlodlo RA; Fujiwara PI
Int J Tuberc Lung Dis; 2019 Feb; 23(2):241-251. PubMed ID: 30808459
[TBL] [Abstract][Full Text] [Related]
13. Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model.
Dowdy DW; Golub JE; Saraceni V; Moulton LH; Cavalcante SC; Cohn S; Pacheco AG; Chaisson RE; Durovni B
J Acquir Immune Defic Syndr; 2014 Aug; 66(5):552-8. PubMed ID: 24853308
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia.
Yirdaw KD; Jerene D; Gashu Z; Edginton ME; Kumar AM; Letamo Y; Feleke B; Teklu AM; Zewdu S; Weiss B; Ruff A
PLoS One; 2014; 9(8):e104557. PubMed ID: 25105417
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting.
Padmapriyadarsini C; Sekar L; Reddy D; Chitra A; Poornagangadevi N; Selvaraj M; Bhavani PK; Mothi SN; Nandagopal K; Vennila S; Tamizhselvan M; Maheshmanisha J; Agarwal U; Rewari BB; Swaminathan S
Indian J Med Res; 2020 Dec; 152(6):648-655. PubMed ID: 34145105
[TBL] [Abstract][Full Text] [Related]
16. Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting.
Rhines AS; Feldman MW; Bendavid E
AIDS; 2018 Sep; 32(15):2129-2140. PubMed ID: 30096067
[TBL] [Abstract][Full Text] [Related]
17. The Drinkers' Intervention to Prevent Tuberculosis (DIPT) trial among heavy drinkers living with HIV in Uganda: study protocol of a 2×2 factorial trial.
Lodi S; Emenyonu NI; Marson K; Kwarisiima D; Fatch R; McDonell MG; Cheng DM; Thirumurthy H; Gandhi M; Camlin CS; Muyindike WR; Hahn JA; Chamie G
Trials; 2021 May; 22(1):355. PubMed ID: 34016158
[TBL] [Abstract][Full Text] [Related]
18. Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature.
Briggs MA; Emerson C; Modi S; Taylor NK; Date A
J Acquir Immune Defic Syndr; 2015 Apr; 68 Suppl 3(Suppl 3):S297-305. PubMed ID: 25768869
[TBL] [Abstract][Full Text] [Related]
19. Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana.
Smith T; Samandari T; Abimbola T; Marston B; Sangrujee N
J Acquir Immune Defic Syndr; 2015 Nov; 70(3):e84-93. PubMed ID: 26258564
[TBL] [Abstract][Full Text] [Related]
20. Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials.
Ayele HT; Mourik MS; Debray TP; Bonten MJ
PLoS One; 2015; 10(11):e0142290. PubMed ID: 26551023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
